Literature DB >> 30770417

Cutting Edge: IL-17B Uses IL-17RA and IL-17RB to Induce Type 2 Inflammation from Human Lymphocytes.

Vladimir Ramirez-Carrozzi1, Naruhisa Ota1, Arivazhagan Sambandam1, Kit Wong1, Jason Hackney2, Nadia Martinez-Martin3, Wenjun Ouyang4, Rajita Pappu5.   

Abstract

IL-17 family cytokines are critical to host defense responses at cutaneous and mucosal surfaces. Whereas IL-17A, IL-17F, and IL-17C induce overlapping inflammatory cascades to promote neutrophil-mediated immunity, IL-17E/IL-25 drives type 2 immune pathways and eosinophil activity. Genetic and pharmacological studies reveal the significant contribution these cytokines play in antimicrobial and autoimmune mechanisms. However, little is known about the related family member, IL-17B, with contrasting reports of both pro- and anti-inflammatory function in rodents. We demonstrate that in the human immune system, IL-17B is functionally similar to IL-25 and elicits type 2 cytokine secretion from innate type 2 lymphocytes, NKT, and CD4+ CRTH2+ Th2 cells. Like IL-25, this activity is dependent on the IL-17RA and IL-17RB receptor subunits. Furthermore, IL-17B can augment IL-33-driven type 2 responses. These data position IL-17B as a novel component in the regulation of human type 2 immunity.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Year:  2019        PMID: 30770417     DOI: 10.4049/jimmunol.1800696

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Infections in the monogenic autoimmune syndrome APECED.

Authors:  Vasileios Oikonomou; Timothy J Break; Sarah L Gaffen; Niki M Moutsopoulos; Michail S Lionakis
Journal:  Curr Opin Immunol       Date:  2021-08-18       Impact factor: 7.268

2.  IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination.

Authors:  Qingli Bie; Hui Song; Xinke Chen; Xiao Yang; Shuo Shi; Lihua Zhang; Rou Zhao; Li Wei; Baogui Zhang; Huabao Xiong; Bin Zhang
Journal:  Oncogene       Date:  2021-03-01       Impact factor: 9.867

Review 3.  Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.

Authors:  Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 4.  Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis.

Authors:  Yun-Juan Nie; Shuo-Hua Wu; Ying-Hua Xuan; Gen Yan
Journal:  Mil Med Res       Date:  2022-05-12

Review 5.  Interleukin-17 Family Cytokines in Metabolic Disorders and Cancer.

Authors:  Eileen Victoria Meehan; Kepeng Wang
Journal:  Genes (Basel)       Date:  2022-09-13       Impact factor: 4.141

Review 6.  From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.

Authors:  Silvia Vidal; Lluís Puig; José-Manuel Carrascosa-Carrillo; Álvaro González-Cantero; José-Carlos Ruiz-Carrascosa; Antonio-Manuel Velasco-Pastor
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

Review 7.  The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer.

Authors:  Jérémy Bastid; Cécile Dejou; Aurélie Docquier; Nathalie Bonnefoy
Journal:  Front Immunol       Date:  2020-04-21       Impact factor: 7.561

Review 8.  IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology.

Authors:  Jasper F Nies; Ulf Panzer
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

Review 9.  Interleukin-17: Potential Target for Chronic Wounds.

Authors:  Yasmin Hadian; Michelle D Bagood; Sara E Dahle; Apra Sood; R Rivkah Isseroff
Journal:  Mediators Inflamm       Date:  2019-11-18       Impact factor: 4.711

Review 10.  Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer.

Authors:  Arianna Brevi; Laura Lucia Cogrossi; Giulia Grazia; Desirée Masciovecchio; Daniela Impellizzieri; Lucrezia Lacanfora; Matteo Grioni; Matteo Bellone
Journal:  Front Immunol       Date:  2020-11-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.